RxDoctor Payments Data

James Dale, DO

Internal Medicine · Luray, VANPI 1336132265

Payments from drug & device makers

$1,295in general payments, 2019–2025

Across 97 payments — averaging $13.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$444
  • Pfizer$168
  • Amgen$123
  • Novartis$109
  • AstraZeneca$103
  • Boehringer Ingelheim$101
  • plus $247 from 7 others

What the payments were for

  • Food & beverage$1,28199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,295 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$429
Medicare patients
52
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban209$204,852
OzempicSemaglutide146$175,266
JardianceEmpagliflozin67$78,504
XareltoRivaroxaban51$61,115
TrulicityDulaglutide22$33,090
FarxigaDapagliflozin Propanediol27$30,703
EntrestoSacubitril/Valsartan17$19,489
Tresiba Flextouch U-100Insulin Degludec29$16,679
Tresiba Flextouch U-200Insulin Degludec13$16,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,722
Breo ElliptaFluticasone/Vilanterol30$11,951
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$10,658
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,378
PaxlovidNirmatrelvir/Ritonavir27$5,717
VascepaIcosapent Ethyl15$5,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$168$210,569236 claims
Novo NordiskOzempic, Levemir$444$179,576161 claims
Boehringer IngelheimJardiance$101$78,50467 claims
Johnson & JohnsonXarelto$39$61,11551 claims
AstraZenecaFarxiga, Breztri Aerosphere$103$40,08141 claims
Lilly USA, LLCTrulicity$72$33,09022 claims
GSKTrelegy Ellipta, Breo Ellipta$13$27,67353 claims
NovartisEntresto$109$19,48917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Luray

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →